Compare Wockhardt with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs AJANTA PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT AJANTA PHARMA WOCKHARDT/
AJANTA PHARMA
 
P/E (TTM) x -23.9 23.5 - View Chart
P/BV x 1.3 4.1 30.4% View Chart
Dividend Yield % 0.0 0.8 0.4%  

Financials

 WOCKHARDT   AJANTA PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
AJANTA PHARMA
Mar-19
WOCKHARDT/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0121,422 71.2%   
Low Rs532898 59.2%   
Sales per share (Unadj.) Rs355.9233.5 152.4%  
Earnings per share (Unadj.) Rs-60.344.0 -137.1%  
Cash flow per share (Unadj.) Rs-46.852.2 -89.7%  
Dividends per share (Unadj.) Rs0.019.00 0.1%  
Dividend yield (eoy) %00.8 0.2%  
Book value per share (Unadj.) Rs257.8255.1 101.1%  
Shares outstanding (eoy) m110.6388.02 125.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.25.0 43.7%   
Avg P/E ratio x-12.826.4 -48.5%  
P/CF ratio (eoy) x-16.522.2 -74.2%  
Price / Book Value ratio x3.04.5 65.8%  
Dividend payout %020.5 -0.1%   
Avg Mkt Cap Rs m85,379102,081 83.6%   
No. of employees `0006.36.8 92.0%   
Total wages/salary Rs m9,3714,307 217.6%   
Avg. sales/employee Rs Th6,295.03,022.6 208.3%   
Avg. wages/employee Rs Th1,498.3633.4 236.6%   
Avg. net profit/employee Rs Th-1,066.3569.1 -187.4%   
INCOME DATA
Net Sales Rs m39,36920,554 191.5%  
Other income Rs m1,202211 570.4%   
Total revenues Rs m40,57120,765 195.4%   
Gross profit Rs m185,664 0.3%  
Depreciation Rs m1,495721 207.5%   
Interest Rs m2,55512 22,025.0%   
Profit before tax Rs m-2,8305,143 -55.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2571,273 20.2%   
Profit after tax Rs m-6,6693,870 -172.3%  
Gross profit margin %027.6 0.2%  
Effective tax rate %-9.124.8 -36.7%   
Net profit margin %-16.918.8 -90.0%  
BALANCE SHEET DATA
Current assets Rs m33,79611,812 286.1%   
Current liabilities Rs m26,9173,776 712.8%   
Net working cap to sales %17.539.1 44.7%  
Current ratio x1.33.1 40.1%  
Inventory Days Days7977 102.5%  
Debtors Days Days8982 109.4%  
Net fixed assets Rs m39,66414,398 275.5%   
Share capital Rs m553175 315.4%   
"Free" reserves Rs m27,96822,277 125.5%   
Net worth Rs m28,52222,452 127.0%   
Long term debt Rs m21,7317 329,259.1%   
Total assets Rs m81,62026,962 302.7%  
Interest coverage x-0.1444.3 -0.0%   
Debt to equity ratio x0.80 259,192.5%  
Sales to assets ratio x0.50.8 63.3%   
Return on assets %-5.014.4 -35.0%  
Return on equity %-23.417.2 -135.7%  
Return on capital %-7.723.0 -33.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80710,682 91.8%   
Fx outflow Rs m1,7892,102 85.1%   
Net fx Rs m8,0198,580 93.5%   
CASH FLOW
From Operations Rs m6843,748 18.3%  
From Investments Rs m6,302-2,228 -282.9%  
From Financial Activity Rs m-7,695-1,475 521.8%  
Net Cashflow Rs m-66445 -1,469.0%  

Share Holding

Indian Promoters % 74.5 73.8 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 1.6 148.4%  
FIIs % 7.7 7.6 101.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 17.0 90.6%  
Shareholders   67,757 20,968 323.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare WOCKHARDT With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 16, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS